DONALD YEE to Male
This is a "connection" page, showing publications DONALD YEE has written about Male.
Connection Strength
0.193
-
Population Pharmacokinetics of Enoxaparin in Pediatric Patients. Ann Pharmacother. 2018 02; 52(2):140-146.
Score: 0.022
-
Population pharmacokinetics of human antithrombin concentrate in paediatric patients. Br J Clin Pharmacol. 2017 Nov; 83(11):2450-2457.
Score: 0.021
-
Evaluation of weight-based dosing of unfractionated heparin in obese children. J Pediatr. 2013 Jul; 163(1):150-3.
Score: 0.016
-
Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr. 2013 Feb; 162(2):293-6.
Score: 0.015
-
Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis. Pediatr Blood Cancer. 2009 Jul; 53(1):100-2.
Score: 0.012
-
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. N Engl J Med. 2026 Apr 09; 394(14):1388-1398.
Score: 0.010
-
Aggregometry detects platelet hyperreactivity in healthy individuals. Blood. 2005 Oct 15; 106(8):2723-9.
Score: 0.009
-
Thromboelastographic and hemostatic characteristics in pediatric patients with sickle cell disease. Arch Pathol Lab Med. 2005 Jun; 129(6):760-5.
Score: 0.009
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
Score: 0.009
-
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. Cancer. 2023 Mar 01; 129(5):685-696.
Score: 0.008
-
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):294-303.
Score: 0.007
-
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27.
Score: 0.006
-
PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design. Thromb Haemost. 2019 May; 119(5):844-853.
Score: 0.006
-
Enoxaparin Population Pharmacokinetics in the First Year of Life. Ther Drug Monit. 2017 12; 39(6):632-639.
Score: 0.005
-
Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017 08 30; 117(9):1705-1713.
Score: 0.005
-
Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism. Pediatr Blood Cancer. 2017 Nov; 64(11).
Score: 0.005
-
Pediatric Acquired von Willebrand Syndrome in Cardiopulmonary Disorders: Do Laboratory Abnormalities Predict Bleeding Risk? J Pediatr Hematol Oncol. 2017 03; 39(2):121-125.
Score: 0.005
-
Validation Study of the Composite Score to Identify Von Willebrand Disease in Children. J Pediatr Hematol Oncol. 2016 Mar; 38(2):139-42.
Score: 0.005
-
Age-related differences in urinary 11-dehydroxythromboxane B2 between infants, children, and adolescents: another example of developmental hemostasis? Pediatr Blood Cancer. 2014 Nov; 61(11):2074-6.
Score: 0.004
-
Catheter-directed thrombolysis for severe pulmonary embolism in pediatric patients. Ann Vasc Surg. 2014 Oct; 28(7):1794.e1-7.
Score: 0.004
-
Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer. 2010 Dec 01; 55(6):1180-4.
Score: 0.003
-
A practical approach to pediatric patients referred with an abnormal coagulation profile. Arch Pathol Lab Med. 2005 Aug; 129(8):1011-6.
Score: 0.002
-
Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9.
Score: 0.002